Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Voxzogo
Pharma
BioMarin drops Voxzogo development for Noonan syndrome
BioMarin cut Voxzogo’s research in children with Noonan syndrome, but not due to safety or efficacy concerns.
Donavyn Coffey
Sep 15, 2026 1:46pm
Ascendis pays 20% royalties in patent settlement with BioMarin
Aug 31, 2026 1:56pm
Trial results set up BioMarin for expansion of Voxzogo
May 21, 2026 10:23am
BioMarin halts dosing, enrollment in 3 midstage Voxzogo studies
Mar 16, 2026 11:26am
FDA approves Ascendis' achondroplasia treatment Yuviwel
Mar 2, 2026 9:25am
BioMarin pulls gene therapy Roctavian off the market
Feb 24, 2026 12:30pm
